Death by HDAC Inhibition in Synovial Sarcoma Cells

Conventional cytotoxic therapies for synovial sarcoma provide limited benefit, and no drugs specifically targeting the causative SS18-SSX fusion oncoprotein are currently available. Histone deacetylase (HDAC) inhibition has been shown in previous studies to disrupt the synovial sarcoma oncoprotein complex, resulting in apoptosis. To understand the molecular effects of HDAC inhibition, RNA-seq transcriptome analysis was undertaken in six human synovial sarcoma cell lines. HDAC inhibition induced pathways of cell-cycle arrest, neuronal differentiation, and response to oxygen-containing species, effects also observed in other cancers treated with this class of drugs. More specific to synovial sarcoma, polycomb group targets were reactivated, including tumor suppressor CDKN2A, and proapoptotic transcriptional patterns were induced. Functional analyses revealed that ROS-mediated FOXO activation and proapoptotic factors BIK, BIM, and BMF were important to apoptosis induction following HDAC inhibition in synovial sarcoma. HDAC inhibitor pathway activation results in apoptosis and decreased tumor burden following a 7-day quisinostat treatment in the Ptenfl/fl;hSS2 mouse model of synovial sarcoma. This study provides mechanistic support for a particular susceptibility of synovial sarcoma to HDAC inhibition as a means of clinical treatment. Mol Cancer Ther; 16(12); 2656–67. ©2017 AACR.

[1]  T. Matsuno,et al.  Morphological and Cytogenetic Studies of a Human Synovial Sarcoma Xenotransplanted into Nude Mice , 1990, Acta pathologica japonica.

[2]  M. Furihata,et al.  Establishment and characterization of a new human synovial sarcoma cell line, HS-SY-II. , 1992, Laboratory investigation; a journal of technical methods and pathology.

[3]  M. Tsuneyoshi,et al.  Overexpression of bcl-2 protein in synovial sarcoma: a comparative study of other soft tissue spindle cell sarcomas and an additional analysis by fluorescence in situ hybridization. , 1996, Human pathology.

[4]  P. Marks,et al.  Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. , 2000, Journal of the National Cancer Institute.

[5]  M. Yoshida,et al.  Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells. , 2000, The Journal of antibiotics.

[6]  N. Jaffe,et al.  Synovial sarcoma in children and adolescents: thirty three years of experience with multimodal therapy. , 2001, Medical and pediatric oncology.

[7]  A. Sandberg,et al.  Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Synovial sarcoma. , 2002, Cancer genetics and cytogenetics.

[8]  Kenji Shimizu,et al.  Establishment and characterization of a biphasic synovial sarcoma cell line, SYO-1. , 2004, Cancer letters.

[9]  Yusuke Nakamura,et al.  Disruption of Fibroblast Growth Factor Signal Pathway Inhibits the Growth of Synovial Sarcomas: Potential Application of Signal Inhibitors to Molecular Target Therapy , 2005, Clinical Cancer Research.

[10]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  C. Lau,et al.  Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC , 2005, Molecular Cancer Therapeutics.

[12]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[13]  T. Mikkelsen,et al.  Genome-wide maps of chromatin state in pluripotent and lineage-committed cells , 2007, Nature.

[14]  Malay Haldar,et al.  A conditional mouse model of synovial sarcoma: insights into a myogenic origin. , 2007, Cancer cell.

[15]  Kristian Helin,et al.  The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. , 2007, Genes & development.

[16]  A. Regev,et al.  An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors , 2008, Nature Genetics.

[17]  T. Mikkelsen,et al.  Genome-scale DNA methylation maps of pluripotent and differentiated cells , 2008, Nature.

[18]  M. van de Rijn,et al.  Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma. , 2008, Cancer research.

[19]  G. Chinnadurai,et al.  BIK, the founding member of the BH3-only family proteins: mechanisms of cell death and role in cancer and pathogenic processes , 2008, Oncogene.

[20]  C. Verrijzer,et al.  SWI/SNF Mediates Polycomb Eviction and Epigenetic Reprogramming of the INK4b-ARF-INK4a Locus , 2008, Molecular and Cellular Biology.

[21]  M. Bollen,et al.  The transcriptional repressor NIPP1 is an essential player in EZH2-mediated gene silencing , 2008, Oncogene.

[22]  W. Talloen,et al.  JNJ-26481585, a Novel Second-Generation Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity , 2009, Clinical Cancer Research.

[23]  S. Grossman,et al.  An ARF/CtBP2 complex regulates BH3-only gene expression and p53-independent apoptosis , 2010, Cell Death and Differentiation.

[24]  H. Yoshikawa,et al.  Synovial Sarcoma Is a Stem Cell Malignancy , 2010, Stem cells.

[25]  T. Nielsen,et al.  EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor , 2010, Oncogene.

[26]  P. Munster,et al.  Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. , 2011, Future oncology.

[27]  Kevin B. Jones,et al.  Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. , 2012, Cancer cell.

[28]  David R. Kelley,et al.  Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks , 2012, Nature Protocols.

[29]  B. Dörken,et al.  p14ARF-induced Apoptosis in p53 Protein-deficient Cells Is Mediated by BH3-only Protein-independent Derepression of Bak Protein through Down-regulation of Mcl-1 and Bcl-xL Proteins , 2012, The Journal of Biological Chemistry.

[30]  G. Crabtree,et al.  Reversible Disruption of mSWI/SNF (BAF) Complexes by the SS18-SSX Oncogenic Fusion in Synovial Sarcoma , 2013, Cell.

[31]  Ø. Bruserud,et al.  PTEN-regulated AKT/FoxO3a/Bim signaling contributes to reactive oxygen species-mediated apoptosis in selenite-treated colorectal cancer cells , 2013, Cell Death and Disease.

[32]  Anushya Muruganujan,et al.  Large-scale gene function analysis with the PANTHER classification system , 2013, Nature Protocols.

[33]  Paula A. Oliveira,et al.  Estimation of rat mammary tumor volume using caliper and ultrasonography measurements , 2013, Lab Animal.

[34]  H. Guchelaar,et al.  Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors , 2014, Anti-cancer drugs.

[35]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[36]  R. Johnstone,et al.  New and emerging HDAC inhibitors for cancer treatment. , 2014, The Journal of clinical investigation.

[37]  T. Nielsen,et al.  A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200†. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[39]  P. Urbánek,et al.  Redox regulation of FoxO transcription factors , 2015, Redox biology.

[40]  Kevin B. Jones,et al.  Modeling synovial sarcoma metastasis in the mouse: PI3′-lipid signaling and inflammation , 2016, The Journal of experimental medicine.

[41]  C. Stiller,et al.  Outcome and the effect of age and socioeconomic status in 1318 patients with synovial sarcoma in the English National Cancer Registry: 1985–2009 , 2016, Clinical Sarcoma Research.

[42]  Torsten O. Nielsen,et al.  Identification of cytotoxic agents disrupting synovial sarcoma oncoprotein interactions by proximity ligation assay , 2016, Oncotarget.

[43]  Li Ding,et al.  The impact of chromosomal translocation locus and fusion oncogene coding sequence in synovial sarcomagenesis , 2016, Oncogene.

[44]  W. Leenders,et al.  Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients , 2016, Annals of Surgical Oncology.

[45]  Kevin B. Jones,et al.  HDAC and Proteasome Inhibitors Synergize to Activate Pro-Apoptotic Factors in Synovial Sarcoma , 2017, PloS one.